Physician profile
Allison Shipp Booth
NPI 1689836652
$861.51
in general payments reported to CMS, 2019-2025
14 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $22.25 · 2021: $23.90 · 2022: $111 · 2023: $183 · 2024: $265 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Abbvie INC. | $121.27 | 2023-2025 | Durysta |
| Genentech USA, INC. | $109.47 | 2019-2025 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $95.20 | 2023-2024 | Eylea Hd, Eylea |
| Alcon Vision LLC | $64.95 | 2022-2023 | Argos |
| Sun Pharmaceutical Industries INC. | $57.98 | 2019-2025 | |
| Biotissue Holdings INC. | $43.50 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $39.21 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $35.03 | 2022 | |
| Allergan, INC. | $24.08 | 2020-2022 | |
| Rxsight INC | $22.78 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $11.97 | 2021 | |
| Omeros Corporation | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.